Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective observational study to determine real-world outcomes in a population from a large electronic medical record database initiating dupilumab

Next Previous
Trial Profile

A retrospective observational study to determine real-world outcomes in a population from a large electronic medical record database initiating dupilumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Benralizumab; Mepolizumab; Omalizumab
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ADVANTAGE-US; US ADVANTAGE
  • Sponsors Regeneron Pharmaceuticals; Sanofi

Most Recent Events

  • 14 Nov 2022 Results (n=2400) assessing the effectiveness of dupilumab in the US, as an add-on treatment in patients with moderate-to-severe asthma, presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
  • 22 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top